Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen.

@article{Salmon2009ClassificationBM,
  title={Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen.},
  author={Stuart Salmon and Heidi Chen and Shuo Chen and Roy S. Herbst and Anne S. Tsao and Hai T. Tran and Alan Sandler and Dean Billheimer and Yu Shyr and In Jae Lee and Pierre P. Massion and Julie Brahmer and J. M. Schiller and David Carbone and Thao P. Dang},
  journal={Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
  year={2009},
  volume={4 6},
  pages={689-96}
}
PURPOSE Although many lung cancers express the epidermal growth factor receptor and the vascular endothelial growth factor, only a small fraction of patients will respond to inhibitors of these pathways. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MS) has shown promise in biomarker discovery, potentially allowing the selection of patients who may benefit from such therapies. Here, we use a matrix-assisted laser desorption/ionization MS proteomic algorithm… CONTINUE READING
Highly Cited
This paper has 72 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

73 Citations

0102030'10'12'14'16'18
Citations per Year
Semantic Scholar estimates that this publication has 73 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
Showing 1-10 of 12 references

Similar Papers

Loading similar papers…